BMI Too Low for GLP-1? Your Real Online Options in 2026

By Weight Loss Provider Guide
Last verified: August 20, 2026

Affiliate disclosure: we may earn a commission if you use some provider links on this page. It does not change what we recommend, and we do not recommend any route that skips a real clinician review.

This is educational information, not medical advice. Only your own clinician can decide what is right for you.

If your BMI is too low for a GLP-1 and you're looking for online options, the honest first answer is this: if you have never taken one of these medications, your BMI is under 27, and you have no diagnosed health condition, no legitimate online program will approve you — and the ones that would are the ones to walk away from.

But that answer only covers one of five situations. And most people who search this are in a different one.

Here's the part almost nobody tells you. If your BMI is low because the medication worked**, you are not in the same conversation at all.** A person who started at BMI 34 and got down to 25 on treatment is a completely different case from a person walking in at 25 for the first time. Same number. Totally different medical question. Most telehealth intake forms can't tell the difference — they only see today's weight — and that single blind spot is why thousands of people get rejected by a form that should have looked at their history instead.

Below, we show you which of the five situations you're actually in, what every major online program's real BMI floor is (one starts at 21 — we'll explain what's behind that door), and exactly what to send a clinician or an insurer to get a fair look.

First, the number one thing to know before you go any further: don't change your weight on an intake form. We'll explain why later, and it's not the reason you think.

Which of these five is you?

Answer capsule: "BMI too low" means five different things, and each one has a different next step. The five are: a first-time request below the threshold, a BMI that dropped because treatment worked, a separate diagnosed condition like type 2 diabetes, an insurance denial, and a measurement that may simply be wrong. Identifying which one applies to you matters more than finding a program that says yes.

Notice something? Four out of five have a real path forward. Only the first one is a hard no, and even that one has an honest next step that isn't "give up."

Why were you told your BMI is too low?

Answer capsule: Three different parties can tell you your BMI is too low, and they mean three different things. A telehealth intake form applies an automated screen. A clinician makes a medical judgment. An insurance company applies a coverage rule. Only the clinician's "no" is a medical decision — the other two can often be worked around with better information.

This is the first thing to sort out, and almost nobody does it. Who actually said no?

Here's why this matters so much. An intake form is a filter, not a doctor. It's built to screen out obvious no-fits fast and cheaply. If you took Wegovy for a year, lost 40 pounds, and now sit at BMI 26, that form sees "26" and stops. It never asks the one question that would change everything: what was your BMI before?

That's not a conspiracy. It's just a badly designed question. But it's costing a lot of people access they should have.

If a form rejected you and you have prior treatment history, you were not medically declined. You were filtered. Those are not the same thing, and the fix is different.

What BMI do you actually need for a GLP-1?

Answer capsule: For weight management, FDA-approved GLP-1 medications are indicated for adults with obesity, or adults with overweight plus at least one weight-related health condition. In practice that means a BMI of 30 or higher, or 27 to 29.9 with a documented condition. Those numbers come from the drug's prescribing information, not from any individual company's policy.

Let's be precise here, because a lot of pages get this slightly wrong.

The drug labels don't literally say "BMI 27." They say the medication is for adults with obesity, or adults with overweight who also have at least one weight-related comorbid condition. The numbers come from how those categories are defined. The CDC puts obesity at BMI 30 and up, and overweight at 25 to 29.9. The prescribing information and standard adult clinical criteria then put the drug-therapy line at 27 with a condition.

Small distinction. Big practical difference: it's a clinical criterion, not a magic number carved into a stone tablet. Which is exactly why the four other situations on this page exist.

Here's where each medication actually sits:

Look at the bottom three rows. That's not a typo. We'll come back to it.

One thing that trips people up constantly: Ozempic and Wegovy are the same molecule. Same drug, different brand, different approval. Asking for "Ozempic for weight loss" without diabetes is asking for off-label use of a diabetes medication. Legal for a doctor to do. Not something a reputable online platform will hand out because you asked nicely.

📎 Want the full breakdown of every qualifying situation, including the Medicare Bridge program and PCOS? That's our companion guide: How to Get a GLP-1 Without Being Overweight*.*

BMI Too Low for GLP-1 Because It Worked? Starting BMI vs. Current BMI

Answer capsule: There is a major difference between starting a GLP-1 at a low BMI and having a low BMI because a GLP-1 already worked. The first is a new prescription request judged on today's numbers. The second is a continuation decision that should consider the pretreatment BMI, the original diagnosis, the response to treatment, and whether stopping is medically wise. Automated intake forms usually cannot tell these apart.

This is the single most important section on this page. If you've taken a GLP-1 before, read it twice.

Two people. Same BMI of 25.5.

Person A has never taken a GLP-1. She's been 25.5 for years. She wants to lose 15 pounds. Standard weight-management criteria don't fit her. A good clinician will say no, and that "no" is correct.

Person B started at BMI 33 with high blood pressure. She took Zepbound for 14 months. Her blood pressure normalized. She's now 25.5. Her insurance just dropped her because "your BMI no longer meets criteria."

Person B is not asking for a new prescription. She's asking whether stopping a treatment that's working is a good idea. That is a completely different medical question, and treating her like Person A is a mistake.

Here's what makes it worse: the evidence says stopping usually undoes it.

In the SURMOUNT-4 trial, people who took tirzepatide for 36 weeks and then switched to placebo regained a large share of what they'd lost within a year — a post-hoc look found 82% of them regained more than a quarter of their lost weight. In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of their prior weight loss within a year.

That's not a reason to stay on medication forever no matter what. It's a reason why "your BMI is fine now, so you're done" isn't automatically good medicine.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, puts it plainly: a clinician may advise staying on weight-management medication long term when it keeps helping and doesn't cause serious side effects. Obesity is treated as a chronic condition. Reaching a goal weight isn't the finish line — for many people it's the point where the treatment is proving it works.

What a clinician actually reviews for continuation

Not just today's number. All of this:

• Your starting weight and BMI, before any medication
• What originally qualified you
• How long you've been on it, at what dose
• How much weight you lost and how fast
• Whether side effects have been manageable
• Whether the condition that qualified you improved (and whether it'd come back)
• Your current weight trend — stable, still dropping, or creeping up
• Whether a lower maintenance dose makes sense
• Whether anything has changed medically

Where "maintenance" is not a valid argument

We'll be straight with you. Prior use isn't a golden ticket. It doesn't hold up when:

• You can't document that you ever had a legitimate prescription
• The prior medication came from a no-prescription seller or a "research peptide" site
• You want to keep losing well past a healthy weight, not maintain
• Something has changed that makes treatment unsafe for you now
• You're using "I used to be on it" as a script rather than a fact

A real continuation case has records behind it. If you have those records, use them. If you don't, that's a different conversation.

✅ NEXT STEP — build your continuation file

If your BMI dropped because treatment worked, the thing standing between you and a fair review is paperwork, not medicine. Pull together your pretreatment weight, your original diagnosis, your prescription history, and your dose record before you talk to anyone.

Build my continuation checklist →

Takes about 60 seconds. It builds a one-page summary you can hand to a clinician or attach to an appeal. No prescription promised — just a document that makes your case for you.

What if my insurance said my BMI is now too low?

Answer capsule: An insurance denial is a coverage decision, not a medical one, and continuation denials are frequently reversible with the right documentation. The key step is getting the denial reason in writing along with the plan's written continuation criteria, then having your prescriber resubmit with the pretreatment BMI, the original qualifying diagnosis, and evidence of your response to treatment.

If your plan cut you off after you succeeded, you're in one of the most common — and most fixable — situations on this page.

The cruel irony isn't lost on anyone: the treatment worked, so they stopped paying for it.

Step 1: Get it in writing

Before you do anything else, call your insurance company and ask for two documents:

1. The exact denial reason, in writing, with the denial code
2. The plan's written criteria for continuation — not for starting, for continuing

Those are two different rule sets at most plans, and a lot of denials happen because the wrong form got submitted.

Step 2: Build the packet

Most continuation appeals turn on the same handful of facts. Get all of them in one place:

Step 3: Ask your prescriber one specific question

Not "can you appeal this." Ask: "Did the original submission include my pretreatment BMI and the diagnosis that first qualified me?"

A surprising number of denials happen because the office submitted a routine refill request with current stats and nothing else. The plan looked at BMI 25 and said no. Nobody ever told them about the 33.

Step 4: Know what cash pay does and doesn't fix

This sentence matters:

Paying cash removes the insurance hurdle. It does not remove the need for a real clinical reason and a clinician's review.

If a clinician thinks continued treatment is appropriate for you, cash pay is a legitimate way to keep going while you fight the coverage battle — or instead of fighting it. If no clinician thinks it's appropriate, cash pay doesn't change that. It just means you found someone willing to take your money.

✅ NEXT STEP — see what your plan actually covers

Before you assume the answer is no, find out where your specific plan stands. Ro runs a free GLP-1 insurance coverage check, and if you need prior authorization, their insurance concierge handles the paperwork and resubmission on your behalf — which is the exact part most people give up on.

Check my coverage and prior-auth path with Ro →

Ro Body membership: $39 for the first month, then $149/month, or as low as $74/month with an annual plan paid upfront. Medication is billed separately. Ro carries Wegovy pill, Wegovy pen, Zepbound KwikPen, Foundayo, and Ozempic.

Best fit if: you have commercial insurance and a documented history that should qualify you. Not the right fit if: you're on Medicare or Medicaid (Ro can't coordinate government plans except FEHB), or you have no qualifying history at all.

The one thing we'll admit that costs us money

Here's our damaging admission, and it's a real one.

Ro will not prescribe below the BMI threshold. Neither will Hers, Hims, Teladoc, or any other program that sticks to FDA-approved medication. If what you want is a program that will approve you at BMI 24 with no diagnosis, Ro is not it, and honestly, neither are we. If that's your priority, there are companies that will say yes — we name several of them in the next section — and you don't need us to find them.

But here's the flip side, and it's the reason we still send people to Ro.

Because Ro holds that line, Ro is the platform that can actually get brand-name Wegovy and Zepbound through your insurance. The insurance concierge, the prior-authorization support, the free coverage checker — those exist because Ro's business is built on people who genuinely qualify. A program built on approving everyone doesn't need any of that machinery, and doesn't have it.

So if you do have a real door — a documented condition, a continuation case, a diagnosis — the strict program is the one that gets you the covered brand-name medication. And if you don't, we'd rather tell you now than take your click.

If the honest answer for you is "not right now," skip ahead to what actually helps in your range*. We put real options there, not a shrug.*

Are there GLP-1 doors that don't check your BMI at all?

Answer capsule: Yes. Several FDA-approved uses of these medications are based on a diagnosis rather than a weight category. Type 2 diabetes medications like Ozempic and Mounjaro carry no BMI requirement in their indications. Wegovy's approval for fatty liver disease with moderate-to-advanced scarring is likewise based on the liver condition, not on body weight.

This surprises almost everyone, so we'll say it clearly: weight is not part of every rule.

The first two rows are the ones people miss. Fatty liver in particular is common and usually silent — a lot of people have it and have never had their liver enzymes checked, let alone had scarring staged.

A hard rule, and we mean it: these are not goals. Nobody should be trying to get one of these conditions or trying to talk their way into a diagnosis they don't have. The point is that a lot of people already have one and have never been tested. If one of these is already true for you, the BMI conversation isn't the conversation you should be having — and the right destination is usually a specialist, not a weight-loss telehealth signup.

📎 Full detail on all of these, plus the Medicare GLP-1 Bridge program and PCOS: How to Get a GLP-1 Without Being Overweight*.*

Three ways your BMI number might be wrong

Answer capsule: Three common errors move a borderline BMI across the line: reporting an outdated height, using a home scale that has drifted out of calibration, and relying on BMI alone when body composition or ancestry makes it a poor fit. A difference of half an inch in height or two pounds on a scale can change a BMI by enough to matter at the threshold.

If you're sitting at 26-point-something and it feels like the universe is trolling you, check your inputs before you accept the answer.

The waist number BMI can't see

BMI uses two things: your height and your weight. That's it. It doesn't know how much of that weight is muscle, or where the fat sits, or what your blood work looks like.

That's not a fringe complaint. In January 2025, The Lancet Diabetes & Endocrinology Commission — 58 experts, nearly 30 months of work — recommended that BMI be treated as a population screening tool rather than a measure of an individual's health, and that excess body fat be confirmed either by direct measurement or by at least one additional number: waist circumference, waist-to-hip ratio, or waist-to-height ratio.

Here's a worked example from the CDC's own writeup of that framework, and it's a good one:

A woman with a BMI of 27, a 36-inch waist, a waist-to-hip ratio of 1.0, and diabetes was classified as merely "overweight" under the old categories. Under the new framework she has stage 2 clinical obesity.

Same body. Same day. Different ruler, different answer.

Waist-to-height ratio is easy to run yourself: divide your waist measurement by your height, using the same units. Above roughly 0.5 is generally considered a flag worth discussing with a clinician.

If you're of Asian ancestry, read this part carefully

The World Health Organization's 2004 Asia-Pacific consultation recommended lower BMI cutoffs for many Asian populations: 23 for overweight and 27.5 for obesity, instead of 25 and 30. The reason is real — at the same BMI, people of Asian ancestry tend to carry more visceral fat and develop type 2 diabetes at lower weights. The American Association of Clinical Endocrinology also screens at 25, or 23 for some ethnicities.

Now the part other pages get wrong. No FDA drug label contains an ethnicity adjustment. And AACE's own treatment algorithm still triggers drug therapy at BMI 27, not 23.

So what does it actually change? It changes your risk picture and what you should be screened for. At BMI 24 with South Asian ancestry, a doctor should be checking your A1c and your waist — because that's a genuinely higher-risk profile than the same BMI in a white patient. And if that screening finds something, that's what opens a door. Not the BMI adjustment itself.

That's not a technicality. It's the difference between walking into an appointment with a real argument and walking in with one that gets dismissed in ten seconds.

✅ NEXT STEP — re-run your number properly

If you've never measured your height barefoot against a wall, do that first. Then re-run it.

Recalculate my BMI and eligibility path →

If it lands at 27 or above, the next question isn't "who will prescribe to me." It's "do I have a condition nobody's checked for?" That's the section below.

Which conditions count — and the tests most people never had

Answer capsule: If your BMI is 27 to 29.9, one documented weight-related condition generally meets standard clinical criteria. The most commonly accepted are high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, and cardiovascular disease. Many people in this BMI range have one of these and have simply never been screened for it.

This is where the most people find an unexpected yes.

About prediabetes: it isn't named in the original weight-management labeling. But it is accepted by many commercial plans and by the CMS Medicare GLP-1 Bridge program at BMI 27 with a cardiovascular risk factor. So the answer is "it depends on who's paying," which is annoying but honest.

About PCOS: it's commonly treated by prescribers as a weight-related condition, and it's not named in the label. Specialists who prescribe for PCOS generally want a documented diagnosis and a real metabolic workup, not a self-report.

The five things worth asking your doctor to check

If you're at BMI 27 to 29.9 and you've never had these run, this is the highest-value thirty minutes available to you:

1. A1c or fasting glucose — catches diabetes and prediabetes
2. Blood pressure — properly measured, not the machine at the grocery store
3. Lipid panel — cholesterol and triglycerides
4. Liver enzymes (ALT and AST) — the first flag for fatty liver
5. A sleep questionnaire — the STOP-BANG is the standard one, and it's free

None of that is about gaming a system. It's about finding out what's actually going on in your body, which is worth knowing whether or not it changes your medication options.

✅ NEXT STEP — find out if a condition opens your door

If you're between 27 and 29.9 and nobody has ever run these, that's the fastest way to a real answer. Ro's evaluation includes a review of your history and, where appropriate, a metabolic lab panel — and if you don't qualify, you're not charged the ongoing membership fee.

See if I qualify with Ro →

$39 first month, then $149/month, or as low as $74/month with an annual plan paid upfront. Medication billed separately.

Prefer to pick your own clinician, or want to compare cash prices across Wegovy, Zepbound, Ozempic, and Foundayo side by side? Compare visit options at Sesame Care → ($59/month on an annual plan, or $99/month. Medication separate.)

Which online programs actually publish a lower BMI floor?

Answer capsule: A small number of online programs publish an eligibility floor below BMI 27, with the lowest at BMI 21. In every case we verified, that lower floor leads to a compounded product rather than an FDA-approved one. No program we found publishes a below-27 door to an FDA-approved GLP-1.

This is the section you came here for, so we're going to give you the actual numbers instead of a vague "some providers may prescribe off-label."

We pulled the published eligibility floor for every major online GLP-1 program we could verify, and paired each one with what product is actually behind that floor. Here's what came out.

The BMI Floor Register — verified August 20, 2026

Sources: each company's own published eligibility page, plus Forbes Health provider reviews (updated May 2026) for Mochi and Ro. Every row screenshotted and dated. See how we verify*.*

What that table actually tells you

Read the last two columns together and a pattern jumps out:

The BMI floor moves with the product, not the medicine.

Every single door below 27 that we found leads to a compounded product. Not one program publishes a below-27 door to an FDA-approved GLP-1.

And the cleanest proof is sitting inside one company.

The provider-policy check

Look at those two Mochi rows again. Same company. Same day. Two different floors.

• Want compounded semaglutide? The floor is 25.
• Want brand-name Wegovy or Zepbound? The floor is 27.

Nothing about the medicine changed between those two rows. Nothing about the patient changed. The rulebook changed, because FDA-approved products come with an FDA-approved indication attached and compounded products don't.

That's the whole answer to "why will some places approve me and others won't," in one table row.

What BMI 21 actually means

Noom's Proactive Health Microdose program opens at BMI 21. For context, the CDC's healthy-weight range is 18.5 to 24.9. Noom itself has said the program covers "the vast majority of US adults."

To be fair to Noom, they publish real exclusions: BMI under 21, pregnancy or breastfeeding, insulin use, an active eating disorder, and certain thyroid and pancreatic conditions. A clinician reviews every applicant. That's more screening than a lot of operators do.

But be clear about what that door is. It's a compounded product, prescribed off-label, for people the FDA-approved medications were never studied in.

What "microdosing" is, and what it isn't

A microdose isn't a gentler, safer version of the medicine. It's a smaller amount of the same molecule.

And here's the structural bit most people never connect: FDA-approved pens come in fixed doses. You can't dial one down to a fraction of the starting dose. So if a program is offering microdoses, it is almost always offering a compounded product — because that's the only way to get a non-standard amount in the vial.

That's why "lower BMI floor" and "compounded" show up together over and over. It isn't a coincidence. It's plumbing.

Novo Nordisk has been direct about this, stating it does not condone misuse of its products and that only the marked doses on the fixed-dose pens are approved medicine.

No CTA in this section, on purpose. These are data rows, not recommendations. Ro sits in this table on exactly the same footing as Noom.

Are compounded GLP-1s a way around the BMI rule?

Answer capsule: No. A compounded medication does not create a medical reason where none exists, and a licensed prescriber still has to judge whether treatment is appropriate. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they reach patients. The legal pathway that made large-scale GLP-1 compounding possible has also been narrowing since 2025.

Let's define the terms, because they get thrown around loosely.

Compounded medication is made by a pharmacy for a specific patient, rather than manufactured and approved as a finished product. Two kinds of pharmacies do it: a 503A pharmacy fills one prescription at a time for one named patient. A 503B outsourcing facility makes larger batches without individual prescriptions. The cheap telehealth GLP-1 boom ran almost entirely on 503B.

We won't tell you compounded medication is "the same" as Wegovy or Ozempic, because that isn't a claim anyone can make.

The safety numbers

As of May 31, 2026, the FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.

Important context, and the FDA says this itself: a report doesn't prove the product caused the event. There's also no denominator — nobody knows exactly how many people used these products — so you can't turn those numbers into a rate. What they do show is a meaningful volume of reports, many involving dosing errors from patients drawing doses out of multi-dose vials.

Why the low-BMI doors are narrowing

This part matters if you're thinking about signing up somewhere.

The reason the shortage mattered: US law lets compounders make copies of an approved drug when it's in shortage. Once the shortage ends, that permission ends with it.

And the FDA has been blunt about the argument compounders made next. The agency has explicitly said that affordability and access do not count as "clinical need." Being cheaper is not a legal justification for copying a drug that's on the shelf.

What this means for you, practically: if you start on a compounded GLP-1 today, the company supplying it may not be able to keep supplying it. That's not fear-mongering — it's a scheduling risk you should price in before you build a year of your health around it.

Narrow exceptions still exist under 503A when there's a documented medical reason the approved product won't work — a genuine allergy to an inactive ingredient, for example. "It costs less" is not one of those reasons.

What actually happens on a GLP-1 when your BMI is lower?

Answer capsule: A lower BMI does not remove a medication's labeled warnings or side effects, and the expected benefit may be smaller or less certain in people outside the populations that were studied. Research also shows that roughly a quarter of the weight lost on GLP-1 medications is lean mass, and that regain after stopping tends to be fat first.

We want to be careful here, because a lot of pages overstate this in both directions.

What we won't say: that these drugs are equally risky at every body size, or that the side effects are identical for everyone. Those are bigger claims than the evidence supports.

What's fair to say: the labeled warnings don't disappear because you weigh less. Nausea, vomiting, gallbladder problems, pancreatitis risk, the thyroid warning — those apply to whoever takes the medication. And the benefits studied in the big trials were measured in people with obesity or overweight plus a condition. If you're not in that group, the size of the benefit is less certain, because you weren't in the study.

Teladoc — a company that sells access to these medications — says it about as plainly as anyone: there's limited data on effectiveness and safety below BMI 27, weight can come off at a rate that adds risk, and the potential benefit may not outweigh that risk.

The muscle question

GLP-1 weight loss is not all fat loss. A review of 22 randomized trials covering 2,258 participants found that roughly 25% of the weight lost on GLP-1 and dual GIP/GLP-1 medications was lean mass. Individual studies range wider — around 12% to 40% for semaglutide, and 14% to 26% for tirzepatide. One MRI-based trial measured about a 6% reduction in thigh muscle volume on tirzepatide.

There's real scientific disagreement here worth knowing about. Researchers at UC Davis have argued that much of the reported "lean mass" loss is liver and organ water rather than skeletal muscle, and that the numbers aren't very different from ordinary calorie restriction. Both readings are defensible. We're giving you both.

The part that should give a lower-BMI reader pause

This is the finding we'd want to know if it were us.

Weight doesn't come back the way it left. In a study of people 12 months after stopping liraglutide, they regained on average 6.3 kg of fat but only 2.5 kg of lean mass.

Read that again. You can land back at the same number on the scale with less muscle underneath it than you started with.

If you have a lot of excess fat to lose, that trade-off is usually worth it — the health gains from losing the fat outweigh it. If you're at BMI 24 trying to lose 12 pounds, the math is a lot less friendly. You have less fat to give and more to lose proportionally.

Dr. Caroline Apovian, an obesity medicine physician at Brigham and Women's Hospital, put the microdosing version of this bluntly: there's a price to pay for it, and the price is that the weight comes back when you stop.

Do I have to gain weight to qualify? And should I fudge the form?

Answer capsule: No to both. Gaining weight to cross an eligibility threshold means taking on the health risk the medication is meant to reduce, and any weight added is weight that then has to come off. Providing inaccurate height or weight on an intake form affects the clinician's risk assessment and dosing decision, creates an inaccurate medical record, and can make later insurance documentation harder.

We're putting this section in because these are two of the most common thoughts on this search, and almost nobody types them out loud. If either one has crossed your mind, you're normal and there's nothing wrong with you.

On gaining weight to qualify

Don't. Not because we're wagging a finger — because the math is terrible.

You'd be adding the exact thing the medication exists to remove, then paying several hundred dollars a month to take it back off, while carrying the added cardiovascular and metabolic risk during the gap. It's the one move on this entire page we'd genuinely ask you not to make.

On rounding the numbers on an intake form

Also don't, and here the reasons are practical rather than moral.

• Dosing decisions use your real weight. A clinician deciding how fast to titrate you is using numbers you gave them.
• It creates a medical record that's wrong, and it follows you.
• It makes a future insurance appeal much harder. If your chart says 190 and your doctor's scale says 178, your continuation packet has a hole in it.
• It doesn't help you as much as you think. A prescriber who'd approve you at 27.1 and reject you at 26.8 isn't looking that closely anyway.

Give them the real number. If the real number doesn't open a door, the honest paths on this page will serve you better than a prescription you obtained by giving bad information.

When wanting this hard is worth a second look

We're going to say this carefully, and we're not going to diagnose anyone.

If your BMI is already in the healthy range and the pull toward these medications feels urgent — if your goal weight would land you well under BMI 20, if you're keeping the search private from people close to you, or if what appeals most is simply not feeling hungry — those are worth talking through with someone before they're worth shopping for.

There's real data behind why we mention it. A JAMA Psychiatry study published in June 2026 surveyed 436 US adults with eating disorders and found that 32.1% reported lifetime GLP-1 use, roughly double the rate in the general adult population, with about 10% reporting lifetime misuse. The authors were careful to note this was a targeted sample and not a population estimate. But it tells you this overlap is real and worth naming.

If any of that lands, the right next call isn't a telehealth signup:

• National Alliance for Eating Disorders Helpline: 1-866-662-1235
• Crisis Text Line: text HOME to 741741
• Our guide: GLP-1s and a history of eating disorders

We're not routing anyone to a provider from this section. That's deliberate.

So what should you actually do? Find yourself here.

Answer capsule: The right next step depends on which of five situations applies. Readers with a documented condition or a continuation history generally need documentation rather than a new provider. Readers below the threshold with no condition and no treatment history are usually better served by screening and a structured plan than by continued provider-shopping.

If you already qualify and just want out of the insurance fight

Some readers do have a documented condition or a real continuation history, and simply don't want to spend three months on appeals. That's a legitimate position. Cash pay is a real option for you.

Brand-name cash pay is the cleanest route: you're getting an FDA-approved medication, and both Ro and Sesame Care publish cash prices for Wegovy, Zepbound, Ozempic, and Foundayo.

Lower-cost compounded programs also exist and they're cheaper. Embody, for example, runs a low-cost cash-pay program with compounded semaglutide and tirzepatide options, weekly injections plus a compounded GLP-1 treatment, fast online onboarding, and 24/7 provider-guided support if treatment is appropriate for you. Its dose flexibility matters for people stepping down to a maintenance dose.

Read this before you click that, though. Everything in the compounded section above applies: these products are not FDA-approved, the FDA does not review them before they reach patients, and the legal pathway that supplies them is narrowing. If continuity of supply matters to you — and for maintenance, it usually does — that's a real consideration, not a footnote. We'd rather you go in knowing than find out in four months.

If the honest answer is "not right now"

If your BMI is under 25, you have no qualifying condition, and you've never taken one of these — our answer is no, and no program that tells you otherwise is telling you something the first eight didn't.

That's not a door closed forever. Weight changes. Health changes. Rules change. And "not a GLP-1 candidate" is genuinely not the same as "nothing can help."

What actually moves the needle in your range:

• A real metabolic workup. A1c, fasting insulin, thyroid panel, lipids, liver enzymes, vitamin D and B12. If something's off, that's a real conversation. If everything's normal, that's useful information too.
• Protein and resistance training. If your goal is 10 to 20 pounds, you're describing body recomposition, not weight management. Roughly 0.7 to 1 gram of protein per pound of goal body weight, lifting 3 to 4 days a week, consistent sleep, and a modest calorie deficit. Unsexy. Longest track record of anything on this page.
• Chase the food noise to its source. Untreated ADHD, chronic short sleep, alcohol patterns, and anxiety all crank up food thoughts. A GLP-1 quiets the noise. So does fixing what's generating it.
• A registered dietitian, if eating patterns are the real issue.
• A therapist, if body image is the real issue. That's a valid thing to need, and it's not something a prescriber can help with.

✅ NEXT STEP — get your specific path

Still not sure which of the five you're in? We walk through your current BMI, your starting BMI, your treatment history, your diagnoses, and who told you no — then route you based on actual fit. Including telling you when the honest answer is "not yet."

Get my personalized action plan →

Some of the paths we recommend earn us nothing. That's on purpose.

What we actually verified

Answer capsule: This page separates four kinds of claims: regulatory facts drawn from FDA labeling and announcements, clinical findings drawn from published research and government health sources, commercial facts drawn from each company's own published pages on a stated date, and editorial conclusions that are labeled as such.

Verified against FDA prescribing information and approval announcements: the weight-management indications for Wegovy injection, Wegovy tablets, Zepbound, Saxenda, and Foundayo; the type 2 diabetes indications for Ozempic, Mounjaro, and Rybelsus; Wegovy's cardiovascular risk indication; Wegovy injection's MASH indication; and Zepbound's obstructive sleep apnea approval.

Verified against government and clinical sources: CDC adult BMI categories; NIDDK guidance on long-term weight-management medication; the Lancet Diabetes & Endocrinology Commission on clinical obesity (January 2025); WHO Asia-Pacific BMI cutoffs; AACE obesity algorithm criteria; SURMOUNT-4 and STEP 1 withdrawal results.

Verified on each company's own published pages, August 20, 2026: the BMI eligibility floors in the register for Ro, Hers/Hims, Teladoc, Mochi Health, AgelessRx, and Noom, cross-checked against Forbes Health provider reviews updated May 2026. Screenshots retained with dates.

What we did not verify: your personal eligibility, your diagnosis, whether your insurance will pay, whether any specific clinician will prescribe for you, or state-by-state telehealth availability on the day you read this. No legitimate program can promise any of those before reviewing your information — and if one does, that's your signal to leave.

Who made this: the Weight Loss Provider Guide research team. We compared FDA labeling and announcements, government health guidance, published clinical research, and each provider's own current eligibility and pricing pages. We do not employ a physician reviewer, and we do not claim to. Where we've drawn a conclusion rather than reported a fact, we've said so.

How we make money: we may earn a commission when readers sign up with Ro, Sesame Care, or Embody through links on this page. It does not change what we recommend. On this page specifically, we have not recommended several higher-paying compounded programs because the medical fit was wrong for what this search is asking. Full details: advertising disclosure.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

Frequently asked questions

Can I get a GLP-1 with a BMI of 25?

Not for weight loss on its own. Standard clinical criteria for weight-management medication start at BMI 30, or 27 with a documented weight-related condition. The answer changes if your BMI is 25 because prior treatment worked, or if you have a separate diagnosed condition like type 2 diabetes.

Can I get a GLP-1 with a BMI of 26?

Generally no for a new weight-loss prescription — 26 sits just below the 27 line even with a condition. Before you accept that, re-measure your height barefoot against a wall and weigh on a medical-grade scale. Small measurement errors move a lot of people across the line at this range.

What is the lowest BMI any online program will accept?

The lowest published floor we found is BMI 21, at Noom's Proactive Health Microdose program. Noom's standard microdose program starts at BMI 25. Both of those doors lead to compounded medication, not FDA-approved medication. No program we verified publishes a below-27 door to an FDA-approved GLP-1.

Is there an FDA-approved GLP-1 with no BMI requirement at all?

Yes, but not for weight loss. The type 2 diabetes medications — Ozempic, Mounjaro, and Rybelsus — carry no BMI requirement because they're approved on the diagnosis. Wegovy injection's approval for fatty liver disease with moderate-to-advanced scarring is likewise based on the liver condition, not on weight.

Can I stay on a GLP-1 after my BMI drops below 27?

Often yes, but it's a clinical decision made case by case. NIDDK notes that a clinician may advise staying on weight-management medication long term when it keeps working and is well tolerated. Bring your pretreatment BMI, your original diagnosis, your dose history, and your response to treatment.

Does insurance use my starting BMI or my current BMI?

It depends on the plan, and on whether you're asking about starting treatment or continuing it. Many plans use different criteria for each. Ask your insurer for its written continuation policy rather than assuming there's a universal rule.

My friend has the same BMI as me and got approved. How?

Usually one of three things: they have a documented condition you don't, they were measured differently, or they used a program with a lower published floor for a compounded product. The BMI Floor Register on this page shows which programs are which.

Does prediabetes count as a qualifying condition?

It isn't named in the original weight-management labeling, but it is accepted by many commercial plans and by the Medicare GLP-1 Bridge program at BMI 27 with a cardiovascular risk factor. Whether it counts for you depends on your specific plan.

Does PCOS qualify me below BMI 27?

PCOS doesn't automatically create a prescription or insurance approval below standard criteria. Some reproductive endocrinologists prescribe off-label with a documented diagnosis and a full metabolic workup. Most weight-loss telehealth platforms aren't set up for that workup.

Is microdosing a way around the BMI rule?

No. A microdose is a smaller amount of the same molecule, not a different or gentler medication. Because FDA-approved pens come in fixed doses, microdosing generally requires a compounded product — which is why lower BMI floors and compounded medication tend to appear together.

Are compounded GLP-1s easier to qualify for?

A compounded product doesn't create a medical reason where none exists, and a licensed prescriber still decides whether treatment is appropriate. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before reaching patients.

Can I transfer an existing GLP-1 prescription to a new online provider?

Some programs evaluate transfers, but policies differ and prior use doesn't guarantee acceptance. Expect to provide your pretreatment BMI, prescription history, current dose, date of last dose, and your reason for transferring.

Do the Asian BMI cutoffs mean I qualify at 23?

Not by themselves. The WHO's lower cutoffs of 23 and 27.5 change how overweight and obesity are defined for many Asian populations, and they reflect genuinely higher metabolic risk at lower weights. But no FDA label includes an ethnicity adjustment. What they should change is what you get screened for — and a screening result is what opens a door.

Is it dangerous to give a higher weight on an intake form?

It creates real problems. Dosing and safety decisions are based on the numbers you provide, it puts inaccurate information in your medical record, and it can undermine a future insurance appeal when your chart and your doctor's scale disagree.

What if I qualified before and my BMI dropped since?

That's a continuation question, not a new prescription request, and it's one of the most common situations on this page. Gather your pretreatment records before you talk to anyone — a form that only sees today's number can't evaluate you fairly.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz.

We'll walk through your current BMI, your starting BMI, your history, your insurance situation, and your goals — and route you based on what actually fits. Including telling you when the honest answer is "not yet."

Last verified: August 20, 2026. FDA labeling, government health guidance, clinical research, and provider eligibility pages checked through this date. Provider policies and pricing change frequently — verify at signup. This page is educational and is not a substitute for medical advice from your own clinician.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

Related guides

• How to Get a GLP-1 Without Being Overweight — the six situations that still qualify
• GLP-1 BMI Eligibility Calculator — run your number
• GLP-1 Insurance & Prior Authorization — how to actually use your plan
• How to Get a GLP-1 Safely Online — verifying a provider and pharmacy
• GLP-1s and a History of Eating Disorders
• Best FDA-Approved GLP-1 Providers — the full comparison

Sources and Verification

Last source check: August 20, 2026. Provider rows describe each company's own public policy, not a promise of approval. Prices can change. Medication eligibility and prescribing decisions belong to a licensed clinician.

• FDA: Concerns with unapproved GLP-1 drugs used for weight loss
• FDA: Current Wegovy prescribing information
• FDA: Current Zepbound prescribing information
• CMS: Medicare GLP-1 Bridge information for providers
• NIDDK: Prescription medications to treat overweight and obesity
• STEP 1 trial extension: Weight regain after semaglutide withdrawal
• SURMOUNT-4 post hoc analysis: Weight regain after tirzepatide withdrawal
• Ro public eligibility and pricing and Ro Body pricing
• Hims public semaglutide eligibility
• Teladoc public GLP-1 eligibility
• Mochi public eligibility
• AgelessRx public Wegovy access criteria
• Noom Med public criteria and Noom Proactive Health criteria